Main Profile

At A Glance

Vandetanib Give Medullary Thyroid Cancer Patients A Second Chance

In April, the U.S. Food and Drug Administration approved the use of vandetanib for the treatment of medullary thyroid carcinoma. MD Anderson's Dr. Robert Gagel who with his team helped to bring about the FDA's approval of vandetanib talks about the drug, the research and it's benefit to medullary thyroid cancer patients.
Length: 03:23

Contact

Questions about Vandetanib Give Medullary Thyroid Cancer Patients A Second Chance

Want more info about Vandetanib Give Medullary Thyroid Cancer Patients A Second Chance? Get free advice from education experts and Noodle community members.

  • Answer

Ask a New Question